CD80 and neoplasm: L929, DC2.4, and Raw264.7 cells were used to assess viability and uptake. BMDCs were used to assess maturation (measured as expression of CD80, CD86, and CCR7).C57BL/6 mice bearing B16F10 tumours were used to assess anticancer effects of prophylactic or therapeutic subcutaneous vaccine injections given 7, 14, and 21 days before tumour inoculation or after tumour establishment.